The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Neogen's revenues will increase 13.8% and EPS will grow 31.8%.
The average estimate for revenue is $51.1 million. On the bottom line, the average EPS estimate is $0.29.
Last quarter, Neogen booked revenue of $50.7 million. GAAP reported sales were 13% higher than the prior-year quarter's $44.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.28. GAAP EPS of $0.28 for Q2 were 27% higher than the prior-year quarter's $0.22 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 53.8%, 330 basis points better than the prior-year quarter. Operating margin was 20.6%, 250 basis points better than the prior-year quarter. Net margin was 13.4%, 170 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $205.1 million. The average EPS estimate is $1.13.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 245 members out of 254 rating the stock outperform, and nine members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Neogen a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neogen is outperform, with an average price target of $47.25.
Is Neogen the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Neogen to My Watchlist.